For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Otsuka: Abilify Props Up Sales, Profits
November 29, 2010
- JCR to Begin Multinational Clinical Trials for LSDs in FY2011: Mr Ashida
November 29, 2010
- Otsuka Wins Abilify Patent Lawsuit in the US
November 29, 2010
- JCR Boosts Production Capacity for Epoetin Biosimilar
November 29, 2010
- Tsumura: Sales, Profits Rise Due to Growth in Ethical Kampo Medicines
November 29, 2010
- Korosho to Ask Drug Firms to Develop 29 More Unapproved Drugs/Indications
November 29, 2010
- JPMA to Organize “Asian Liaison Conference”
November 29, 2010
- End of R&D Tax Break to Result in Tax Increases for Pharma Industry: PMDA
November 29, 2010
- BioWa Licenses POTELLIGENT Technology to Agensys
November 29, 2010
- Otsuka Applies for Mucosta Eye Drop for Dry Eye
November 29, 2010
- Rohto: Record-High Profits despite Flat Sales
November 29, 2010
- Otsuka Applies for Levocarnitine Based on Published Evidence
November 29, 2010
- GSK to Launch Switch OTC Steroidal Agent
November 29, 2010
- Nippon Kayaku Applies for LCH for Exal Based on Data from Public Domain
November 29, 2010
- Wakamoto: Sales Down 5.0% Due to NHI Price Cuts
November 22, 2010
- Tsumura Diversifies Crude Drugs Procurement Sources
November 22, 2010
- Korosho Kicks Off Research Team to Increase Popularity of Switch OTC Drugs
November 22, 2010
- Meiji Seika: Sales Up 10.4% Driven by Generics
November 22, 2010
- Kyowa Kirin: Pharma Sales Up 0.7%
November 22, 2010
- Teva-Kowa, Taisho Pharm. Ind. Integrate R&D Divisions
November 22, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…